S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
BREAKING: Tiny biotech successfully treats blindness (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Modern Day Options Trading For Beginners! (Ad)pixel
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
BREAKING: Tiny biotech successfully treats blindness (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Modern Day Options Trading For Beginners! (Ad)pixel
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
BREAKING: Tiny biotech successfully treats blindness (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Modern Day Options Trading For Beginners! (Ad)pixel
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
BREAKING: Tiny biotech successfully treats blindness (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Modern Day Options Trading For Beginners! (Ad)pixel
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
NASDAQ:ALNY

Alnylam Pharmaceuticals - ALNY Short Interest Ratio & Short Volume

$195.12
-0.79 (-0.40%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$190.85
$197.92
50-Day Range
$182.66
$233.37
52-Week Range
$117.58
$242.97
Volume
544,019 shs
Average Volume
815,067 shs
Market Capitalization
$24.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$245.74

Alnylam Pharmaceuticals Short Interest Data

Current Short Volume
4,930,000 shares
Previous Short Volume
5,390,000 shares
Change Vs. Previous Month
-8.53%
Dollar Volume Sold Short
$915.75 million
Short Interest Ratio / Days to Cover
6.3
Last Record Date
March 15, 2023
Outstanding Shares
124,130,000 shares
Percentage of Shares Shorted
3.97%
Today's Trading Volume
544,019 shares
Average Trading Volume
815,067 shares
Today's Volume Vs. Average
-33.25%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Alnylam Pharmaceuticals ?

Sign up to receive the latest short interest report for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ALNY Short Interest Over Time

ALNY Days to Cover Over Time

ALNY Percentage of Float Shorted Over Time

Alnylam Pharmaceuticals (NASDAQ:ALNY) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/15/20234,930,000 shares $915.75 million -8.5%N/A6.3 $185.75
2/28/20235,390,000 shares $1.03 billion +5.7%N/A7 $191.45
2/15/20235,100,000 shares $1.13 billion -4.3%N/A6.5 $222.10
1/31/20235,330,000 shares $1.21 billion -6.2%N/A7.1 $226.40
1/15/20235,680,000 shares $1.34 billion +11.2%N/A7.3 $235.53
12/30/20225,110,000 shares $1.21 billion -5.4%N/A6.2 $237.65
12/15/20225,400,000 shares $1.24 billion +8.2%N/A6.1 $229.37
11/30/20224,990,000 shares $1.10 billion -10.3%N/A5.1 $220.59
11/15/20225,560,000 shares $1.19 billion -7.8%N/A5.7 $214.29
10/31/20226,030,000 shares $1.25 billion +25.6%N/A6.1 $207.26
10/15/20224,800,000 shares $890.54 million +5.7%N/A4.2 $185.53
9/30/20224,540,000 shares $908.73 million +3.7%N/A4.2 $200.16
9/15/20224,380,000 shares $913.14 million +4.3%N/A4.2 $208.48
8/31/20224,200,000 shares $868.01 million -16.0%N/A4 $206.67
8/15/20225,000,000 shares $1.16 billion +1.4%N/A5.2 $231.01
7/31/20224,930,000 shares $700.26 million -1.2%N/A4.9 $142.04
7/15/20224,990,000 shares $725.50 million +4.2%N/A5.8 $145.39
6/30/20224,790,000 shares $698.62 million +1.1%N/A5.5 $145.85
6/15/20224,740,000 shares $642.03 million -15.7%5.0%5.4 $135.45
5/31/20225,620,000 shares $707.00 million -4.1%N/A6.8 $125.80
5/15/20225,860,000 shares $741.11 million -1.0%N/A6.7 $126.47
4/30/20225,920,000 shares $789.91 million +2.3%N/A7 $133.43
4/15/20225,790,000 shares $968.90 million +11.8%N/A7.1 $167.34
3/31/20225,180,000 shares $845.84 million +9.5%N/A6.4 $163.29
3/15/20224,730,000 shares $723.31 million +3.7%N/A5.4 $152.92
2/28/20224,560,000 shares $719.80 million +3.9%N/A5.2 $157.85
2/15/20224,390,000 shares $672.99 million +8.1%N/A5.3 $153.30
1/31/20224,060,000 shares $558.66 million +2.8%3.6%5.1 $137.60
1/15/20223,950,000 shares $586.58 million +11.9%N/A4.8 $148.50
12/31/20213,530,000 shares $598.62 million -6.1%N/A4.6 $169.58
12/15/20213,760,000 shares $718.39 million -4.8%N/A5.1 $191.06
11/30/20213,950,000 shares $726.01 million -2.5%N/A6.5 $183.80
11/15/20214,050,000 shares $701.91 million +4.9%N/A6.8 $173.31
10/29/20213,860,000 shares $615.90 million -0.5%N/A6.4 $159.56
10/15/20213,880,000 shares $809.21 million -3.2%N/A7.1 $208.56
9/30/20214,010,000 shares $757.13 million -9.3%N/A6.7 $188.81
9/15/20214,420,000 shares $828.66 million -8.5%N/A7 $187.48
8/31/20214,830,000 shares $972.91 million -3.6%N/A7.2 $201.43
8/13/20215,010,000 shares $984.67 million -1.0%N/A7.3 $196.54
7/30/20215,060,000 shares $905.44 million +19.9%N/A7.7 $178.94













ALNY Short Interest - Frequently Asked Questions

What is Alnylam Pharmaceuticals' current short interest?

Short interest is the volume of Alnylam Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 4,930,000 shares of ALNY short. Learn More on Alnylam Pharmaceuticals' current short interest.

What is a good short interest ratio for Alnylam Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALNY shares currently have a short interest ratio of 6.0. Learn More on Alnylam Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Alnylam Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Alnylam Pharmaceuticals: Portman Square Capital LLP, Jane Street Group LLC, Centiva Capital LP, Jefferies Financial Group Inc., Susquehanna International Group LLP, CSS LLC IL, Pura Vida Investments LLC, Twin Tree Management LP, Barclays PLC, JPMorgan Chase & Co., Bank of America Corp DE, Group One Trading L.P., Citigroup Inc., Cutler Group LLC CA, Simplex Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Alnylam Pharmaceuticals' short interest increasing or decreasing?

Alnylam Pharmaceuticals saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 4,930,000 shares, a decrease of 8.5% from the previous total of 5,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Alnylam Pharmaceuticals' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Alnylam Pharmaceuticals: BioMarin Pharmaceutical Inc. (3.35%), United Therapeutics Co. (2.89%), Vertex Pharmaceuticals Incorporated (1.14%), Regeneron Pharmaceuticals, Inc. (1.16%), Genmab A/S (0.47%), Horizon Therapeutics Public Limited (1.77%), BeiGene, Ltd. (2.09%), Catalent, Inc. (3.69%), Sarepta Therapeutics, Inc. (6.18%), and Viatris Inc. (1.98%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($3.66 billion), Occidental Petroleum Co. ($2.62 billion), Coinbase Global, Inc. ($2.38 billion), T. Rowe Price Group, Inc. ($2.13 billion), Verisk Analytics, Inc. ($2.08 billion), Snowflake Inc. ($1.95 billion), Paramount Global ($1.78 billion), Etsy, Inc. ($1.60 billion), Teck Resources Limited ($1.51 billion), and Voya Financial, Inc. ($1.49 billion). View all of the most shorted stocks.

What does it mean to sell short Alnylam Pharmaceuticals stock?

Short selling ALNY is an investing strategy that aims to generate trading profit from Alnylam Pharmaceuticals as its price is falling. ALNY shares are trading down $0.79 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Alnylam Pharmaceuticals?

A short squeeze for Alnylam Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALNY, which in turn drives the price of the stock up even further.

How often is Alnylam Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALNY, twice per month. The most recent reporting period available is March, 15 2023.



This page (NASDAQ:ALNY) was last updated on 3/31/2023 by MarketBeat.com Staff